US approves vaccine against mosquito-borne chikungunya virus

The United States Food and Drug Administration (FDA) has approved the first vaccine against chikungunya, developed by the European group Valneva, health authorities said.

The mosquito-borne disease, which causes fever and joint pains and can be fatal to newborns. Even although deaths are rare, it is seen as an “emerging global health threat”.

Approval by the FDA of the single-dose vaccine for people aged 18 and above is expected to speed up its rollout worldwide.

People in tropical and subtropical regions of Africa, Southeast Asia, and parts of the Americas are at the highest risk of infection.

Mosquitos carrying the chikungunya virus are endemic in these areas.

However, it has spread to new parts of the world, causing an increase in cases, including in Europe.

Valneva has also filed an application with the European Medicines Agency (EMA).

In the absence of any preventive treatment to date, the only way to protect oneself was to avoid being bitten.

According to the FDA, at least five million cases of chikungunya have been recorded in the last 15 years.

Kindly give us two minute from your time to follow our social handles... Click on social media logo below to follow...Thanks

About Zacnetwork

I'm Zaccheaus Adeyemi Ogunwale by name, a computer scientist with multimedia art/lens skills. A CEO of Zacnetwork/Naijatrackz subcidiary of Zac Media House. Zacnetwork ✅ A computer scientist that specialize in blogging, Promotion and Distribution of songs, both in Locals and internation Digital Music Platforms, Also to the Top Website, Instagram, Twitter PR, Broadcasting Audiomark Promotion. NaijaTrackz/Gospelnoise ✅ Specialised in Entertainment platform that provide a unique latest news of celebrities, download of latest musics. Finally, I'm CEO of for 3years,now, expands to or

Check Also

Osimhen prefers Arsenal, Chelsea to PSG move

0share Facebook0 Twitter0 LinkedIn0 Reddit0 Email0 Nigerian forward Victor Osimhen would rather join one of …

Leave a Reply

Share via
Send this to a friend